Details
Structure visualisation
Entry information
| Complex | |
| AACDB_ID: | 1602 |
| PDBID: | 5NHR |
| Chains: | AB_D |
| Organism: | Homo sapiens |
| Method: | XRD |
| Resolution (Å): | 3.35 |
| Reference: | 10.1073/pnas.1707925114 |
| Antibody | |
| Antibody: | Bimagrumab Fv |
| Antibody mutation: | No |
| INN (Clinical Trial): | Bimagrumab(Phase-II) |
| Antigen | |
| Antigen: | Activin receptor type-2B |
| Antigen mutation: | No |
| Durg Target: | |
Sequence information
Antibody
Heavy Chain: A
Mutation: NULL
| >5NHR_A|Chain B[auth A], D[auth H]|Bimagrumab Fv heavy-chain|Homo sapiens (9606) QVQLVQSGAEVKKPGASVKVSCKASGYTFTSSYINWVRQAPGQGLEWMGTINPVSGSTSYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGGWFDYWGQGTLVTVSSHHHHHH |
Light Chain: B
Mutation: NULL
| >5NHR_B|Chain A[auth B], C[auth L]|Bimagrumab Fv Light-Chain|Homo sapiens (9606) QSALTQPASVSGSPGQSITISCTGTSSDVGSYNYVNWYQQHPGKAPKLMIYGVSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCGTFAGGSYYGVFGGGTKLTVLWSHPQFEK |
Antigen
Chain: D
Mutation: NULL
| >5NHR_D|Chain E[auth C], F[auth D]|Activin receptor type-2B|Homo sapiens (9606) GPKAMAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIELVKKGCWLDDFNCYDRQECVATEENPQVYFCCCEGNFCNERFTHLP |
Interaction
1、Solvent accessible surface areas (SASA) were calculated (Naccess V2.1.1) for each residue in antibody and antigen, respectively. The residues with SASA loss in binding of more than 1Å2 were classified as interacting residues.
Interacting residues (ΔSASA based)
| B: TYR32 ASN33 TYR34 LEU48 TYR51 LYS55 PRO57 SER58 PHE93 GLY96 SER97 TYR98 A: VAL2 TYR27 THR28 THR30 SER31 SER32 TYR33 ASN52 PRO53 VAL54 SER55 SER57 ARG72 THR74 SER75 ARG98 GLY99 GLY100 TRP101 ASP103 TYR104 D: LEU38 GLU39 GLU47 GLU52 GLN53 ASP54 LYS55 ARG56 TYR60 SER62 VAL73 LYS74 CYS77 TRP78 LEU79 ASP80 ASP81 PHE82 ASN83 TYR85 THR93 VAL99 PHE101 |
2、We defined interacting paratope-epitope residues by a distance cutoff of < 5Å . Two amino acids are considered as interacting residues if they have at least one atom within a distance of 5 Å from any atom.
Interacting residues (Atom distance based)
